Modified virus takes on tough tumors in early trial
Disease control
Recruiting now
This early-stage study tests a new treatment called VG2062, a modified virus designed to attack cancer cells. It is for 30 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the best dose for future studies.
Phase: PHASE1 • Sponsor: Shanghai Virogin Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC